Soranib (Sorafenib) - 200mg (30 Tablets)
our best price : $213.95
Sorafenat (Sorafenib Tosylate) - 200mg (120 Tablets)
our best price : $425.00
Tagrix (Osimertinib Mesylate) - 80mg (30 Tablets)
our best price : $1837.50
Apatinib Mesylate Tablets - 0.25g (10 Tablets)
our best price : $838.95
Votrient contains the active ingredient Pazopanib and is indicated in the treatment of advanced renal cell carcinoma and in the treatment of advanced soft tissue sarcoma (STS) in patients who have who have received prior chemotherapy.
The recommended starting dose of Votrient is 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal).
In renal cell carcinoma, the initial dose reduction should be 400mg, and additional dose decrease or increase should be in 200mg steps based on individual tolerability.
In soft tissue sarcoma, a decrease or increase should be in 200mg steps based on individual tolerability.
Patients with hepatic impairment may need further dosage adjustments. Check with your doctor.
Signs of an allergic reaction including hives, difficult breathing, or swelling of the face, lips, tongue, or throat will require urgent medical attention.
More serious side effects of Votrient include:
If you notice any of the above side effects, contact your doctor as soon as possible.
Less severe side effects you may notice can include:
Severe and sometimes fatal hepatotoxicity has occurred during clinical trials. Hepatic function must be carefully monitored so that treatment can be interrupted, reduced, or discontinued as needed.
Pazopanib is not recommended during pregnancy as there is a chance of it harming the unborn baby. It is uncertain if Pazopanib is passed through breastmilk.
Before taking Votrient, make sure your doctor is aware of all medicines you are currently taking, and all past and present health conditions.
Votrient can interfere with wound healing. Be aware of this if requiring surgery and try to avoid skin cuts where possible.